Skip to main content

Pressure Bio to Raise $843K in Direct Offering

NEW YORK (GenomeWeb News) – Pressure BioSciences today said that it has entered into definitive agreements with certain investors for a registered direct offering of 843 units priced at $1,000 per unit.

Each unit sold will consist of one share of Series D convertible preferred stock, which is convertible into approximately 1,539 shares of common stock; and a Series F warrant to purchase approximately 614 shares of common stock at an exercise price of $.81 per share, exercisable for five years from the initial exercise date, which is six months after the date of issuance.

Proceeds from the offering will be used to support Pressure Bio's commercialization strategy, which includes expansion of its internal sales and marketing team, its non-US distribution network, and strategic partnerships.

The firm expects to close the offering on Friday.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.